Journal of Substance Abuse Treatment
Volume 37, Issue 3 , Pages 277-285 , October 2009

A randomized clinical trial of methadone maintenance for prisoners: Results at 12 months postrelease

  • Timothy W. Kinlock, Ph.D.

      Affiliations

    • Social Research Center, Friends Research Institute, Baltimore, MD 21201, USA
    • Division of Criminology, Criminal Justice, and Forensic Studies, University of Baltimore, Baltimore, MD 21201, USA
    • Corresponding Author InformationCorresponding author. Social Research Center, Friends Research Institute, Inc., Baltimore, MD 21201, USA. Tel.: +1 410 837 3977; fax: +1 410 752 4218.
    • ,
  • Michael S. Gordon, D.P.A.

      Affiliations

    • Social Research Center, Friends Research Institute, Baltimore, MD 21201, USA
    • ,
  • Robert P. Schwartz, M.D.

      Affiliations

    • Social Research Center, Friends Research Institute, Baltimore, MD 21201, USA
    • Open Society Institute, Baltimore, MD 21201, USA
    • ,
  • Terrence T. Fitzgerald, M.D.

      Affiliations

    • Glenwood Life Counseling Center, Baltimore, MD 21212, USA
    • ,
  • Kevin E. O'Grady, Ph.D.

      Affiliations

    • Department of Psychology, University of Maryland, College Park, MD 20742, USA

Received 8 October 2008 ,Revised 25 February 2009 ,Accepted 2 March 2009.

References 

  1. Agresti A. Categorical data analysis. New York: Wiley; 1990;
  2. Anglin MD. The efficacy of civil commitment in treating narcotic addiction. National Institute on Drug Abuse Research Monograph. 1988;86:8–34
  3. Ball JC, Ross A. The effectiveness of methadone maintenance treatment: Patients, programs, services, and outcomes. New York, NY: Springer; 1991;
  4. Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison—A high risk of death for former inmates. New England Journal of Medicine. 2007;356:157–165
  5. Bird SM, Hutchinson SJ. Male drugs-related deaths in the fortnight after release from prison, Scotland, 1996–99. Addiction. 2003;98:185–190
  6. Butzin CA, Martin SS, Inciardi JA. Evaluating component effects of a prison-based treatment continuum. Journal of Substance Abuse Treatment. 2002;22:63–99
  7. Centers for Disease Control . Epidemiology of HIV/AIDS—United States, 1981. Morbidity and Mortality Weekly Reports. 2006;55:589–592
  8. Chaiken JM, Chaiken MR. Drugs and predatory crime. In:  Tonry M,  Wilson JQ editor. Drugs and crime: Crime and justice: A Review of Research. Vol. 13:Chicago: University of Chicago Press; 1990;p. 203–219
  9. Chitwood D, Comerford M, Weatherby N. The initiation and use of heroin in the age of crack. In:  Inciardi JA,  Harrison LD editor. Heroin in the age of crack-cocaine. Thousand Oaks, CA: Sage; 1998;p. 51–76
  10. Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomized controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug and Alcohol Dependence. 2003;72:59–65
  11. Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak A. Four-year follow-up of imprisoned male heroin users and methadone treatment: Mortality, re-incarceration, and hepatitis C infection. Addiction. 2005;100(6):820–828
  12. Dole V, Robinson J, Orraga J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. New England Journal of Medicine. 1969;280:1372–1375
  13. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology. 2002;36:S210–S219
  14. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) . EMCDDA annual report. Brussels: Author; 2002;
  15. Farrell M, Marsden J. Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction. 2008;103:251–255
  16. Gordon MS, Kinlock TW, Schwartz RP, O'Grady KE. A randomized clinical trial of methadone maintenance for prisoners: Findings at 6-months post-release. Addiction. 2008;103:1333–1342
  17. Gorta, A. (1992). Monitoring the New South Wales methadone program: 1986-1991. Research Publication No. 25, 1992; November: New South Wales Department of Corrective Services (ISSN 0813 5800).
  18. Gossop M. Treating drug misuse problems: Evidence of effectiveness. London: National Treatment Agency for Substance Misuse; 2006;
  19. Greenfield L, Fountain D. Influence of time in treatment and follow-up duration on methadone treatment outcomes. Journal of Psychopathology and Behavioral Assessment. 2000;22:353–364
  20. Greenfield SF, Brooks AJ, Gordon SM, Green CA, Kropp F, McHugh RK, et al. Substance abuse treatment entry, retention, and outcome in women: A review of the literature. Drug and Alcohol Dependence. 2007;86:1–21
  21. Hanlon TE, Nurco DN, Bateman RW, O'Grady KE. The response of drug abuser parolees to a combination of treatment and intensive supervision. The Prison Journal. 1998;78:31–44
  22. Hanlon TE, Nurco DN, Kinlock TW, Duszynski KR. Trends in criminal activity and drug use over an addiction career. American Journal of Drug and Alcohol Abuse. 1990;16:223–228
  23. Herget G. Methadone and buprenorphine added to the WHO list of essential medicines. HIV AIDS Policy Law Review. 2005;10:23–24
  24. Hiller ML, Knight K, Simpson DD. Risk factors that predict dropout from corrections-based treatment for drug abuse. The Prison Journal. 1999;79:411–430
  25. Hosmer D, Lemeshow S. Applied logistic regression. New York: Wiley; 1989;
  26. Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Archives of General Psychiatry. 2001;58:503–508
  27. Hume S, Gorta A. The effects of the NSW prison methadone program on criminal recidivism and retention in methadone treatment. In: Evaluation of the NSW Department of Corrective Services Prison Methadone Program. Study No. 7. Sydney: Research and Statistics Division, New South Wales Department of Corrective Services; 1989;
  28. Inciardi JA, McBride D, Surratt H. The heroin street addict: Profiling a national population. In:  Inciardi JA,  Harrison LD editor. Heroin in the age of crack-cocaine. Thousand Oaks, CA: Sage; 1998;p. 31–50
  29. Joe GW, Simpson DD, Broome KM. Retention and patient engagement models for different treatment modalities in DATOS. Drug and Alcohol Dependence. 1999;57:113–125
  30. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine. 2000;343:1290–1297
  31. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): A review of historical and clinical issues. Mount Sinai Journal of Medicine. 2000;67:347–364
  32. Jurgens R. Is the world finally waking up to HIV/AIDS in prisons?. Infectious Disease in Corrections Report. 2004, September;7(9):
  33. Kerr T, Jurgens R. Methadone maintenance therapy in prisons: Reviewing the evidence. Montreal: Canadian HIV/AIDS Legal Network; 2004;
  34. Kinlock TW, Battjes RJ, Schwartz RP. A novel opioid maintenance program for prisoners: Preliminary findings. Journal of Substance Abuse Treatment. 2002;22:141–147
  35. Kinlock TW, Battjes RJ, Schwartz RP. A novel opioid maintenance treatment program for prisoners: Report of post-release outcomes. American Journal of Drug and Alcohol Abuse. 2005;31:433–454
  36. Kinlock TW, Gordon MS, Schwartz RP, O'Grady KE. A study of methadone maintenance for male prisoners: 3-Month post-release outcomes. Criminal Justice and Behavior. 2008;35:34–47
  37. Kinlock TW, Gordon MS, Schwartz RP, O'Grady KE, Fitzgerald T, Wilson M. A randomized clinical trial of methadone maintenance for prisoners: Results at 1-month post-release. Drug and Alcohol Dependence. 2007;91:220–227
  38. Kinlock TW, O'Grady KE, Hanlon TE. Prediction of the criminal activity of incarcerated drug-abusing offenders. Journal of Drug Issues. 2003;33:897–920
  39. Kinlock, T. W., Schwartz, R. P., & Gordon, M. S. (2005). The significance of interagency collaboration in developing opioid agonist programs for inmates. Corrections Compendium, 30, 6–9, 28–30.
  40. Leukefeld CG, Tims FM, Farabee D. Treatment of drug offenders: Policies and issues. New York, NY: Springer; 2002;
  41. MacGowan RJ, Swanson NM, Brackbill RM, Rugg DL, Barker T, Molde S. Retention in methadone maintenance treatment programs, Connecticut and Massachusetts, 1990–1993. Journal of Psychoactive Drugs. 1996;28:259–265
  42. Maddux JF, Desmond DP. Careers of opioid users. New York, NY: Praeger; 1981;
  43. Magura S, Nwakeze P, Demsky S. Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction. 1998;93:51–61
  44. Magura S, Rosenblum A, Lewis C, Joseph H. The effectiveness of in-jail methadone maintenance. Journal of Drug Issues. 1993;23:75–99
  45. Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug and Alcohol Dependence. 2001;61(2):195–206
  46. McCullough P, Nelder JA. Generalized linear models. 2nd ed. London: Chapman and Hall; 1989;
  47. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The fifth edition of the Addiction Severity Index: Historical critique and normative data. Journal of Substance Abuse Treatment. 1992;9:199–213
  48. McSweeney T, Turnbull PJ, Hough M. Review of criminal justice interventions for drug use in other countries. London: Criminal Policy Research Unit; 2002;
  49. Michels II, Stover H, Gerlach R. Substitution treatment for opioid addicts in Germany. Harm Reduction Journal. 2007;2:4–5
  50. Moolchan ET, Hoffman JA. Phases of treatment: A practical approach to methadone maintenance treatment. International Journal on Addiction. 1994;29:135–160
  51. Nurco DN. A long-term program of research on drug use and crime. Substance Use and Misuse. 1998;33:1817–1837
  52. Nurco DN, Hanlon TE, Kinlock TW. Recent research on the relationship between illicit drug use and crime. Behavioral Sciences and the Law. 1991;9:221–242
  53. Pang L, Hao Y, Mi G, Wang C, Luo W, Rou K, et al. Effectiveness of first eight methadone maintenance treatment clinics in China. AIDS. 2007;21(Suppl 8):S103–S107
  54. Peles E, Adelson M. Gender differences and pregnant women in a methadone maintenance treatment (MMT) clinic. Journal of Addictive Diseases. 2006;25:39–45
  55. Platt JJ, Widman M, Lidz V, Marlowe D. Methadone maintenance treatment: Its development and effectiveness after 30 years. In:  Inciardi JA,  Harrison LD editor. Heroin in the age of crack-cocaine. Thousand Oaks, CA: Sage; 1998;p. 160–187
  56. Prendergast ML, Wexler HK. Correctional substance abuse treatment programs in California: A historical perspective. Prison Journal. 2004;84:61–80
  57. Rowan-Szal GA, Chatham LR, Simpson DD. Importance of identifying cocaine and alcohol-dependent methadone clients. American Journal of Addiction. 2000;9:38–50
  58. Schwartz RP, Highfield DA, Jaffe JH, Brady JV, Butler CA, Rouse CO, et al. A randomized controlled trial of interim methadone maintenance. Archives of General Psychiatry. 2006;63:102–109
  59. Smith-Rohrberg D, Bruce RD, Altice FL. Research note-review of corrections-based therapy for opiate-dependent patients: Implications for buprenorphine treatment among correctional populations. Journal of Drug Issues. 2004;34:451–480
  60. Stewart LM, Henderson CJ, Hobbs MS, Ridout SC, Knuiman WW. Risk of death in prisoners after release from jail. Australian and New Zealand Journal of Public Health. 2004;28(1):32–36
  61. Tomasino V, Swanson AJ, Nolan J, Shuman H. The Key Extended Entry Program (KEEP): A methadone treatment program for opiate-dependent inmates. Mount Sinai Journal of Medicine. 2001;68:14–20
  62. Weatherburn D, Lind B. Heroin harm minimization: Do we really have to choose between law enforcement and treatment?. New South Wales Crime and Justice Bulletin. 1999;46:1–11

PII: S0740-5472(09)00030-0

doi: 10.1016/j.jsat.2009.03.002

Journal of Substance Abuse Treatment
Volume 37, Issue 3 , Pages 277-285 , October 2009

Article Tools

* Image Usage & Resolution